Efficacy of Topiramate in Preventing Recurrences and Headaches Associated with Idiopathic Intracranial Hypertension: Study Protocol

Topiramate, FDA approved for migraine prophylaxis, is a promising treatment in IIH because it can reduce ICP, aid weight-loss, and reduce associated headaches. There is little literature about the course and recurrence rate of IIH after discontinuation of standard treatment with acetazolamide. According to two studies, the recurrence rate of the disease is 33-40% in an adult population after acetazolamide cessation